Drug Trial Radar · NCT00140582
Primary Rituximab and Maintenance
Last checked: Nov 20, 2026Latest source record: Mar 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,217
Actual
Start
Dec 2004
Primary completion
May 2007
Study completion Dec 2016
Sponsor
- Lead sponsor
- Lymphoma Study AssociationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- HOVON - Dutch Haemato-Oncology Association; German Low Grade Lymphoma Study Group; Australasian Leukaemia and Lymphoma Group; Institute of Cancer Research, United Kingdom
- First posted
- Sep 1, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
* Objectives * Primary objective: To evaluate in patients with advanced follicular lymphoma the benefit of maintenance therapy with rituximab after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy * Secondary objective: To evaluate response rates, event driven survival endpoints (EFS, PFS, OS) and quality of life of four different chemotherapy regimens combined with rituximab, with or without maintenance with rituximab, for first line treatment of advanced stage follicular lymphoma. * Study Design This is an international open-label, multicentre, randomized study with two treatment phases. In the induction phase patients have to respond to 1st line induction treatment in order to be eligible for randomization to the second phase of maintenance treatment or observation. After the maintenance period patients will be included in the follow up phase for 3 years.
Conditions
- Follicular Lymphoma
Interventions
RituximabDrug
rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: number of event observed driven : 344 events or 10 years
Locations
24 sites in 12 countries. Site status is shown where the registry gives one.
Fundaleu Hospital
Buenos Aires, Argentina
Australian Leukemia and Lymphoma Group
Melbourne, Australia
Université de Gent
Ghent, Belgium
Groupe d'Etude des Lymphomes de l'adulte
Mont-Godinne, Belgium
Hospital Samaritano
São Paulo, Brazil
Fundación Santafé de Bogotá
Bogotá, Colombia
Amtssygehuset i Herlev
Herlev, Denmark
Polyclinique Bordeaux Nord
Bordeaux, France
Hôpital Henri Mondor
Créteil, France
Hématologie CHU de Lille
Lille, France
Centre Léon Bérard
Lyon, France
Institut Curie
Paris, France
Hôpital Saint Louis
Paris, France
Hématologie Adultes - Hôpital Necker
Paris, France
Service d'Hématologie - Centre Hospitalier Lyon-Sud
Pierre-Bénite, France
Centre Hospitalier Robert Debré
Reims, France
Centre Henri Becquerel
Rouen, France
Hématologie CHU Purpan
Toulouse, France
Institut Gustave Roussy
Villejuif, France
HOVON
Utrecht, Netherlands
Australia New Zealand Leukemia Lymphoma Group
Auckland, New Zealand
Instituo Nacional de Enfermedades Neoplasicas
Lima, Peru
Hospital Clinic Barcelona
Barcelona, Spain
King Chulalongkorn Memorial Hospital
Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.